Anixa Biosciences (NASDAQ:ANIX) Advances Cancer Therapies and Vaccines, Analysts Reiterate 'Buy' Ratings

• Anixa Biosciences (NASDAQ:ANIX) is showcasing significant pipeline progress with presentations on its ovarian cancer therapy, lira-cel, and a breast cancer vaccine.
• Leading analyst firms H.C. Wainwright and Citigroup have reiterated "Buy" ratings for Anixa Biosciences, signaling strong market confidence.
• Both the ovarian cancer therapy and breast cancer vaccine have achieved positive clinical trial milestones, with lira-cel showing promising survival observations and the vaccine successfully completing Phase 1.

Anixa Biosciences (NASDAQ:ANIX) is a biotechnology company that develops therapies and vaccines to fight cancer. It has a market capitalization of approximately $84.04 million. Market capitalization is the total value of a company's shares, calculated by multiplying the share price by the number of shares outstanding.

The company announced it will present two of its immunotherapy programs at a symposium in New York. This news highlights progress in its pipeline. Following this, analyst firms H.C. Wainwright and Citigroup both reiterated their "Buy" ratings for Anixa Biosciences on June 12, 2026, when the stock price was $2.48.

One presentation will focus on its ovarian cancer therapy, lira-cel, which is in a Phase 1 clinical trial. The study is showing positive survival observations. Currently, the stock for Anixa Biosciences is priced at $2.47, with a daily trading volume of 91,763 shares. The stock has traded between $2.42 and $2.52 today.

Another presentation will cover Anixa's breast cancer vaccine. This vaccine has successfully completed a Phase 1 trial, meeting all its main goals and proving to be safe. Over the past 52 weeks, the stock has reached a high of $5.46 and a low of $2.32, showing significant price movement over the year.